Terms ending in 2039
Every in-force patent on Celgene Corporation's record whose computed term ends in 2039, whoever holds it now. Soonest term end first, then patent number.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 11,626,210 | Digital Health Prognostic Analyzer for Multiple Myeloma Mortality Predictions In force · High confidence | Celgene Corporation | In force | High confidence | |
| US 12,474,342 | Methods for Treating Cancer and the Use of Biomarkers as a Predictor of Clinical Sensitivity to Therapies In force · High confidence | Celgene Corporation | In force | High confidence | |
| US 11,401,336 | Bcma-Binding Antibodies and Uses Thereof In force · High confidence | Celgene Corporation | In force | High confidence | |
| US 11,505,522 | Processes for the Preparation of (S)-TERT-BUTYL 4,5-Diamino-5-Oxopentanoate In force · High confidence | Celgene Corporation | In force | High confidence | |
| US 11,644,461 | Methods for Measuring Small Molecule Affinity to Cereblon In force · High confidence | Celgene Corporation | In force | High confidence | |
| US 11,358,952 | Substituted 4-Aminoisoindoline-1,3-Dione Compounds, Compositions Thereof, and Methods of Treatment Therewith In force · High confidence | Celgene Corporation | In force | High confidence | |
| US 11,357,775 | Combination Therapies Comprising Apremilast and TYK2 Inhibitors In force · High confidence | Celgene Corporation | In force | High confidence | |
| US 10,969,381 | Methods for Treating Multiple Myeloma and the Use of Companion Biomarkers for 4-(4-(4-(((2-(2,6-Dioxopiperidin-3-YL)-1-Oxoisoindolin-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-Fluorobenzonitrile In force · High confidence | Celgene Corporation | In force | High confidence | |
| US 11,726,080 | Methods for Treating Multiple Myeloma and the Use of Companion Biomarkers for 4-(4-(4-(((2-(2,6-Dioxopiperidin-3-YL)-1-Oxoisoindolin-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-Fluorobenzonitrile In force · High confidence | Celgene Corporation | In force | High confidence | |
| US 12,510,533 | Methods for Treating Multiple Myeloma and the Use of Companion Biomarkers for 4-(4-(4-(((2-(2,6-Dioxopiperidin-3-YL)-1-Oxoisoindolin-4-YL)OXY)METHYL)BENZYL)PIPERAZIN-1-YL)-3-Fluorobenzonitrile In force · High confidence | Celgene Corporation | In force | High confidence | |
| 18 more term ends in 2039 · Pro | |||||
10 of 28 patents shown. Soonest term end first, then patent number.
Pro members see all 28.
26 of these are in force and held by Celgene Corporation.
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.